The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients
- 3 July 2002
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 118 (1), 330-336
- https://doi.org/10.1046/j.1365-2141.2002.03554.x
Abstract
Summary. In 1997, the Italian Ministry of Health created a special programme for the controlled distribution of deferiprone to collect data and to evaluate its safety and effectiveness in long‐term use. Five hundred and thirty‐two thalassaemia patients from 86 treatment centres were enrolled in this programme. One hundred and eighty‐seven patients (32%) experienced a total of 269 events that led to a temporary interruption or, in some cases, to a discontinuation of treatment. The incidence of agranulocytosis and milder neutropenias were 0·4/100 and 2·1/100 patient‐years respectively. Neutropenia occurred predominantly in younger and non‐splenectomized patients. Transient alanine transaminase increase, gastrointestinal discomfort and arthralgia were the other most commonly reported events. Ferritin levels showed a significant decrease in time after 3 years of therapy. This is the largest number of deferiprone‐treated patients to have been reported to date. These data show that the drug was effective in reducing serum ferritin levels and the incidence of adverse events was not greater than the frequency reported in clinical trials.Keywords
This publication has 21 references indexed in Scilit:
- The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1)Transfusion Science, 2000
- Safety profile of the oral iron chelator deferiprone: a multicentre studyBritish Journal of Haematology, 2000
- Factors Influencing Effectiveness of Deferiprone in a Thalassaemia major Clinical SettingActa Haematologica, 2000
- Iron Chelation with Oral Deferiprone in Patients with ThalassemiaNew England Journal of Medicine, 1998
- Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia MajorNew England Journal of Medicine, 1998
- Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron ChelatorsBritish Journal of Haematology, 1995
- Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia MajorNew England Journal of Medicine, 1995
- Deferiprone‐associated myelotoxicityEuropean Journal of Haematology, 1994
- Arthropathy in thalassaemia patients receiving deferiproneThe Lancet, 1994
- Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trialBritish Journal of Haematology, 1992